Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2012 First Quarter Earnings
July 05 2011 - 8:00AM
Business Wire
Forest Laboratories, Inc. (NYSE: FRX), an international
manufacturer and marketer of pharmaceutical products, will release
its Fiscal 2012 First Quarter financial results before the U.S.
stock market opens on Tuesday, July 19, 2011. At 10:00 AM EDT,
Forest will host a conference call where Frank Perier, Executive
Vice President Finance & Administration and Chief Financial
Officer, and Dr. Marco Taglietti, Senior Vice President Research
& Development and President, Forest Research Institute, will
discuss the financial results and relevant company and industry
topics. The conference call will be webcast live beginning at 10:00
AM EDT on the Company's website www.frx.com and also on the website
www.streetevents.com. Please log on to either website at least
fifteen minutes prior to the conference call as it may be necessary
to download software to access the call. A replay of the conference
call will be available until August 2, 2011 at both websites and
also by dialing 1-800-642-1687 (US and Canada) or +1-706-645-9291
(international), Conference Call ID # 80419236.
About Forest
Laboratories
Forest Laboratories’ (NYSE: FRX) longstanding global
partnerships and track record developing and marketing
pharmaceutical products in the United States have yielded its
well-established central nervous system and cardiovascular
franchises and innovations in anti-infective and respiratory
medicine. The Company’s pipeline, the most robust in its history,
includes product candidates in all stages of development across a
wide range of therapeutic areas. The Company is headquartered in
New York, NY. To learn more, visit www.FRX.com.
Except for the historical information contained herein, this
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories’ Annual Report on Form 10-K, Quarterly Report on Form
10-Q, and any subsequent SEC filings.
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2023 to Jun 2024